



This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (currently amended): A method of treating preventing cataracts, retinopathy, lens cell damage and retinal cell damage caused by diabetes a diabetic complication in the eye comprising administering to a patient an effective amount of one or more compounds of the formula:



or



wherein:

T is independently CR, NR, N, S or O;


X is independently O, NR, N or S;

Y is independently O, NR, N or S;

Z is independently C, N, S or O;

a is 0 or 1;

R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are, independently, R,



wherein R is independently H, OH, alkyl, alkenyl or alkynyl, an aromatic ring system, amino, sulphydryl, or sulfonyl, M is a divalent alkyl, alkenyl or alkynyl, aromatic ring system, or sulfonyl, W is Cl, F, Br or OCl, and A is an aromatic ring system;

R<sup>2</sup>, R<sup>8</sup> and R<sup>9</sup> are independently R as defined above; and


R<sup>6</sup> is independently R, NH<sub>2</sub>, OH, or OCOR where R is as set forth above;

R<sup>7</sup> is independently OH or H; or

R<sup>6</sup> and R<sup>7</sup> taken together are O;

and pharmaceutically acceptable salts or esters of the foregoing, as well as optical isomers thereof.


Claim 2 (original): The method of claim 1, wherein said patient is a dog and said compound is:



Claim 3 (original): The method of claim 2, wherein the compound is administered orally.

Claim 4 (original): The method of claim 2, wherein the compound is administered topically.

Claim 5 (original): The method of claim 1, wherein said patient is a human and said compound is:




Claim 6 (original): The method of claim 5, wherein the compound is administered orally.


Claim 7 (original): The method of claim 5, wherein the compound is administered topically.

Claim 8 (withdrawn): A method of inhibiting aldose reductase activity in cells, comprising

contacting the cells with an effective amount of a compound of formula:



or



wherein:

T is independently CR, NR, N, S or O;


X is independently O, NR, N or S;

Y is independently O, NR, N or S;

Z is independently C, N, S or O;


a is 0 or 1,

R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are, independently, R,



wherein R is independently H, OH, alkyl, alkenyl or alkynyl, an aromatic ring system, amino, sulphydryl, or sulfonyl, M is a divalent alkyl, alkenyl or alkynyl, aromatic ring system, or sulfonyl, W is Cl, F, Br or OCl, and A is an aromatic ring system;  
 R<sup>2</sup>, R<sup>8</sup> and R<sup>9</sup> are independently R as defined above; and  
 R<sup>6</sup> is independently R, NH<sub>2</sub>, OH, or OCOR where R is as set forth above;  
 R<sup>7</sup> is independently OH or H; or  
 R<sup>6</sup> and R<sup>7</sup> taken together are O;  
 and pharmaceutically acceptable salts or esters of the foregoing, as well as optical isomers thereof.


Claim 9 (withdrawn): The method of claim 8, wherein said patient is a dog and said compound is:



Claim 10 (withdrawn): The method of claim 9, wherein the compound is administered orally.

Claim 11 (withdrawn): The method of claim 9, wherein the compound is administered topically.


Claim 12 (withdrawn): The method of claim 8, wherein said patient is a human and said compound is:




Claim 13 (withdrawn): The method of claim 12, wherein the compound is administered orally.

Claim 14 (withdrawn): The method of claim 12, wherein the compound is administered topically.

Claim 15 (withdrawn): A method of treating retinopathy comprising:  
administering to a patient an effective amount of a compound of formula:



or



wherein:

T is independently CR, NR, N, S or O;


X is independently O, NR, N or S;

Y is independently O, NR, N or S;

Z is independently C, N, S or O;

a is 0 or 1,

R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are, independently, R,



wherein R is independently H, OH, alkyl, alkenyl or alkynyl, an aromatic ring system, amino, sulphydryl, or sulfonyl, M is a divalent alkyl, alkenyl or alkynyl, aromatic ring system, or sulfonyl, W is Cl, F, Br or OCl, and A is an aromatic ring system;

R<sup>2</sup>, R<sup>8</sup> and R<sup>9</sup> are independently R as defined above; and

R<sup>6</sup> is independently R, NH<sub>2</sub>, OH, or OCOR where R is as set forth above;

R<sup>7</sup> is independently OH or H; or


R<sup>6</sup> and R<sup>7</sup> taken together are O;

and pharmaceutically acceptable salts or esters of the foregoing, as well as optical isomers thereof.

Claim 16 (withdrawn): The method of claim 15, wherein the compound is administered orally.

Claim 17 (withdrawn): The method of claim 15, wherein the compound is administered topically.


Claim 18 (withdrawn): The method of claim 15, wherein said patient is a dog, and said compound is



Claim 19 (withdrawn): A method of decreasing the loss of PKC in diabetic patients comprising administering to a patient an effective amount of one or more compounds of claim 1.


Claim 20 (withdrawn): A method of inhibiting polyol accumulation in diabetic patients comprising administering to a patient an effective amount of one or more compounds of claim 1.

Claim 21 (withdrawn): A pharmaceutical composition comprising a compound with formula:




wherein the compound is useful to treat a disorder associated with the activity of aldose reductase.

Claim 22 (withdrawn): A method of preparing a pharmaceutical composition comprising: bringing a compound of formula:



or



wherein:

T is independently CR, NR, N, S or O;


X is independently O, NR, N or S;

Y is independently O, NR, N or S;

Z is independently C, N, S or O;


a is 0 or 1,

R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are, independently, R,




wherein R is independently H, OH, alkyl, alkenyl or alkynyl, an aromatic ring system, amino, sulphydryl, or sulfonyl, M is a divalent alkyl, alkenyl or alkynyl, aromatic ring system, or sulfonyl, W is Cl, F, Br or OCl, and A is an aromatic ring system;  
 R<sup>2</sup>, R<sup>8</sup> and R<sup>9</sup> are independently R as defined above; and  
 R<sup>6</sup> is independently R, NH<sub>2</sub>, OH, or OCOR where R is as set forth above;  
 R<sup>7</sup> is independently OH or H; or  
 R<sup>6</sup> and R<sup>7</sup> taken together are O;  
 and pharmaceutically acceptable salts or esters of the foregoing, as well as optical isomers thereof, into association with a pharmaceutically acceptable carrier.

Claim 23 (withdrawn): A compound selected from the group consisting of compounds of formula:



or



wherein:

T is independently CR, NR, N, S or O;


X is independently O, NR, N or S;

Y is independently O, NR, N or S;

Z is independently C, N, S or O;

a is 0 or 1,

R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are, independently, R,



wherein R is independently H, OH, alkyl, alkenyl or alkynyl, an aromatic ring system, amino, sulphydryl, or sulfonyl, M is a divalent alkyl, alkenyl or alkynyl, aromatic ring system, or sulfonyl, W is Cl, F, Br or OCl, and A is an aromatic ring system;

R<sup>2</sup>, R<sup>8</sup> and R<sup>9</sup> are independently R as defined above; and

R<sup>6</sup> is independently R, NH<sub>2</sub>, OH, or OCOR where R is as set forth above;

R<sup>7</sup> is independently OH or H; or

R<sup>6</sup> and R<sup>7</sup> taken together are O;

provided that either:

T is independently CR, provided that R is not H, or NR;

X is independently NR or N, provided that R is not H;

Y is independently NR, provided that R is not H; or


R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are, independently,

-CH(OR)-OR; -O-CH(OR)-R; -M-O-CH(OR)-R; -M-C(OR)-C(=O)-R; or -M-C(=O)-


C(OR)OR.

**Claim 24 (currently amended): A method of treating an ocular diabetic complication symptom or condition selected from the group consisting of: retinopathy, loss of PKC in eye lens cells, polyol accumulation in the eye, galactitol formation from galactose in lens cells, vascular leakage in the eye,**

and expression of aldose reductase in the retina comprising administering to a patient an effective amount of one or more compounds of the formula:



or



wherein:

T is independently CR, NR, N, S or O;


X is independently O, NR, N or S;

Y is independently O, NR, N or S;

Z is independently C, N, S or O;

a is 0 or 1;

R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are, independently, R,



wherein R is independently H, OH, alkyl, alkenyl or alkynyl, an aromatic ring system, amino, sulphydryl, or sulfonyl, M is a divalent alkyl, alkenyl or alkynyl, aromatic ring system, or sulfonyl, W is Cl, F, Br or OCl, and A is an aromatic ring system;

R<sup>2</sup>, R<sup>8</sup> and R<sup>9</sup> are independently R as defined above; and

R<sup>6</sup> is independently R, NH<sub>2</sub>, OH, or OCOR where R is as set forth above;

R<sup>7</sup> is independently OH or H; or

R<sup>6</sup> and R<sup>7</sup> taken together are O;

and pharmaceutically acceptable salts or esters of the foregoing, as well as optical isomers thereof.